CLASS data FOR NOVEL APPROACH TO CANCER treatmentParsortix system used to identify patients with highly metastatic CTC clusters for targeted treatmentNew treatment strategy provides 'uncharted ...

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...

Sales ResultSignificant progress in all operating areas; stable fourth quarter leads to annual sales of EUR 12.2 million (+6%) 24.01.2025 / 07:00 CET/CESTThe issuer is solely responsible for the ...

Revolutionizing healthcare through AI, blockchain, and interoperability, the region is setting new standards for sustainable, patient-centric care. DOHA, QA / ACCESS Newswire / January 23, 2025 / The ...

SAN DIEGO, CA / ACCESS Newswire / January 23, 2025 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology company focused on the treatment ...

DALLAS, TX / ACCESS Newswire / January 23, 2025 / Formula Wellness, a premier provider of integrated aesthetics and wellness services, is proud to formally announce Amar K. Thakrar, PharmD, MBA, as ...

As Federal Budget Cuts Threaten Healthcare Systems, RCM Vendors and Providers Strategize for Resilience WASHINGTON, D.C., WASHINGTON, D.C. / ACCESS Newswire / January 23, 2025 / Proposed federal ...

HOUSTON, TEXAS / ACCESS Newswire / January 23, 2025 / US Med-Equip (USME) the nation's highest-rated provider of medical equipment rentals, sales, biomedical support and asset management service, ...

CAMBRIDGE, MA AND PITTSBURGH, PA / ACCESS Newswire / January 23, 2025 / Next Gen Diagnostics (NGD), a pioneer in the development of machine learning models for whole genome sequence- (WGS-) based ...

Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, ...

Glp-1 Analogues Market OverviewThe Glp analogues market size is expected to be worth USD 606.3 billion by 2034.The target market was valued at USD 45.3 billion in 2024.The market is projected to grow ...

Oliver Weber joined Körber on 2 January 2025 as Chief Executive Officer (CEO) Software in the Business Area Pharma. In this role, he will lead the global software business of the Business Area Pharma.